Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250558 | 1.00 | DDB1 (0.45) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL6023255 | 0.92 | DDB1 (0.44) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL19331754 | 0.86 | DDB1 (0.44) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL19342217 | 0.86 | DDB1 (0.40) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL28461374 | 0.86 | DDB1 (0.41) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL656014 | 0.86 | DDB1 (0.44) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL31339121 | 0.86 | NR1H2 (0.49) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL19342216 | 0.85 | DDB1 (0.42) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL2255165 | 0.85 | DDB1 (0.42) | DDB1CRBNNR1H2MAPTMEN1 | |
| SCHEMBL2255164 | 0.85 | DDB1 (0.42) | DDB1CRBNNR1H2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | disclosed |
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-2066678-A1 | SPIRO ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270375-A1 | SPIRO ANTIBIOTIC DERIVATIVES | NR0B1, NRDC, NR4A1 | DDB1 670/4885CRBN 40/4885NR1H2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.